{"organizations": [], "uuid": "51087203dc20e96f9b29d0cbc7be1af61226c810", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/03/07/the-associated-press-conatus-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Conatus reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-07T23:35:00.000+02:00", "replies_count": 0, "uuid": "51087203dc20e96f9b29d0cbc7be1af61226c810"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/03/07/the-associated-press-conatus-reports-4q-loss.html", "ord_in_thread": 0, "title": "Conatus reports 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "conatus pharmaceuticals inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Wednesday reported a loss of $4.4 million in its fourth quarter.\nThe San Diego-based company said it had a loss of 15 cents per share.\nThe results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.\nThe biotechnology company posted revenue of $8.8 million in the period, which fell short of Street forecasts. Five analysts surveyed by Zacks expected $9.6 million.\nFor the year, the company reported that its loss narrowed to $17.4 million, or 61 cents per share. Revenue was reported as $35.4 million.\nConatus shares have risen 49 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $6.88, a climb of 59 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on CNAT at https://www.zacks.com/ap/CNAT", "external_links": [], "published": "2018-03-07T23:35:00.000+02:00", "crawled": "2018-03-08T00:11:29.003+02:00", "highlightTitle": ""}